These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1319710)

  • 1. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge.
    Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST
    Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation.
    Ishizaka ST; Mishkin EM
    Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge.
    Landolfi V; Zarley CD; Abramovitz AS; Figueroa N; Wu SL; Blasiak M; Ishizaka ST; Mishkin EM
    Vaccine; 1993; 11(4):407-14. PubMed ID: 8385842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge.
    Ghiasi H; Cai S; Slanina S; Nesburn AB; Wechsler SL
    Antiviral Res; 1995 Oct; 28(2):147-57. PubMed ID: 8585768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes.
    Eis-Hübinger AM; Schmidt DS; Schneweis KE
    J Gen Virol; 1993 Mar; 74 ( Pt 3)():379-85. PubMed ID: 8383173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
    Martin S; Cantin E; Rouse BT
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
    Dropulic LK; Oestreich MC; Pietz HL; Laing KJ; Hunsberger S; Lumbard K; Garabedian D; Turk SP; Chen A; Hornung RL; Seshadri C; Smith MT; Hosken NA; Phogat S; Chang LJ; Koelle DM; Wang K; Cohen JI
    J Infect Dis; 2019 Aug; 220(6):990-1000. PubMed ID: 31058977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T-cell-induced prevention of HSV-1 keratitis by immunization with the synthetic peptide of glycoprotein D].
    Heiligenhaus A; Berra A; Dutt JE; Zhao TZ; Wells PA; Foster CS
    Ophthalmologe; 1994 Oct; 91(5):608-16. PubMed ID: 7812092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
    Wachsman M; Luo JH; Aurelian L; Paoletti E
    Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.